Goulis I, Elefsiniotis I, Karatapanis S, Koskinas J, Ioannidou P, Manolakopoulos S, Vlachogiannakos J, Oikonomopoulou M, Samonakis DN, Manesis EK, et al. High efficacy of the currently recommended regimens of 2 Direct Acting Antivirals (DAAs)+/-Ribavirin (R) in HCV genotype 4 (GT4) patients (pts) with advanced fibrosis or cirrhosis in HERACLIS real world cohort. In: HEPATOLOGY. Vol. 66. WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017. pp. 815A–816A. Copy at http://www.tinyurl.com/23e56js4